@article{3e572bf41ce843198c8b86b4cd2101d4,
title = "Impact of chronic kidney disease and diabetes on clinical outcomes in women undergoing PCI",
abstract = "Background: For women undergoing drug-eluting stent (DES) implantation, the individual and combined impact of chronic kidney disease (CKD) and diabetes mellitus (DM) on outcomes is uncertain. Aims: We sought to assess the impact of CKD and DM on prognosis in women after DES implantation. Methods: We pooled patient-level data on women from 26 randomised controlled trials comparing stent types. Women receiving DES were stratified into 4 groups based on CKD (defined as creatine clearance <60 mL/min) and DM status. The primary outcome at 3 years after percutaneous coronary intervention was the composite of all-cause death or myocardial infarction (MI); secondary outcomes included cardiac death, stent thrombosis and target lesion revascularisation. Results: Among 4, 269 women, 1, 822 (42.7%) had no CKD/DM, 978 (22.9%) had CKD alone, 981 (23.0%) had DM alone, and 488 (11.4%) had both conditions. The risk of all-cause death or MI was not increased in women with CKD alone (adjusted hazard ratio [adj. HR] 1.19, 95% confidence interval [CI]: 0.88-1.61) nor DM alone (adj. HR 1.27, 95% CI: 0.94-1.70), but was significantly higher in women with both conditions (adj. HR 2.64, 95% CI: 1.95-3.56; interaction p-value <0.001). CKD and DM in combination were associated with an increased risk of all secondary outcomes, whereas alone, each condition was only associated with all-cause death and cardiac death. Conclusions: Among women receiving DES, the combined presence of CKD and DM was associated with a higher risk of the composite of death or MI and of any secondary outcome, whereas alone, each condition was associated with an increase in all-cause and cardiac death.",
keywords = "death, diabetes, drug-eluting stent, miscellaneous, renal insufficiency, NLA, n/a OA procedure",
author = "Alessandro Spirito and Dipti Itchhaporia and Samantha Sartori and Edoardo Camenzind and Alaide Chieffo and Dangas, {George D.} and Soren Galatius and Jeger, {Raban V.} and Kandzari, {David E.} and Adnan Kastrati and Kim, {Hyo Soo} and Takeshi Kimura and Leon, {Martin B.} and Mehta, {Laxmi S.} and Mikhail, {Ghada W.} and Morice, {Marie Claude} and Johny Nicolas and Brunna Pileggi and Serruys, {Patrick W.} and Smits, {Pieter C.} and Steg, {P. Gabriel} and Stone, {Gregg W.} and Marco Valgimigli and Birgit Vogel and {von Birgelen}, Clemens and Giora Weisz and William Wijns and Stephan Windecker and Roxana Mehran",
note = "Funding Information: A. Spirito received a research grant from the Swiss National Science Foundation (SNSF). R.V. Jeger reports research and educational grants to the institution from Abbott, Amgen, AstraZeneca, Bayer, Biosense Webster, B. Braun Melsungen AG, Biotronik, Boston Scientific, Bristol-Myers Squibb, Cordis, Daiichi Sankyo, Edwards Lifesciences, GE Medical Systems, MCM Medsys, Medtronic, Novartis, Pfizer, Terumo, and Vascular Medical GmbH. G.W. Stone has received speaker honoraria from Medtronic, Pulnovo, Infraredx, Abiomed, and Abbott; has served as a consultant to Daiichi Sankyo, Valfix, TherOx, Robocath, HeartFlow, Ablative Solutions, Vectorious, Miracor, Neovasc, Ancora, Elucid Bio, Occlutech, CorFlow, Apollo Therapeutics, Impulse Dynamics, Cardiomech, Gore, Amgen, Adona Medical, and Millennia Biopharma; and has equity/options from Ancora, Cagent, Applied Therapeutics, the Biostar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Valfix, and Xenter; his daughter is an employee at IQVIA. G.W. Stone{\textquoteright}s employer, Mount Sinai Hospital, receives research support from Abbott, Abiomed, Bioventrix, Cardiovascular Systems Inc, Philips, Biosense-Webster, Shockwave, Vascular Dynamics, Pulnovo, and V-Wave. P.G. Steg reports receiving research grants from Amarin, Bayer, Sanofi, and Servier; compensation for work on clinical trials (steering committee, clinical events committee or data safety and monitoring board) from Amarin, AstraZeneca, Bayer, Bristol-Myers Squibb, Idorsia, Novartis, PhaseBio, Pfizer, Sanofi, and Servier; for consulting or speaking from Amarin, Amgen, BMS/ Myokardia, Merck, Novo Nordisk, and Regeneron; and is a Senior Associate Editor at Circulation. S. Windecker reports research, travel or educational grants to the institution from Abbott, Abiomed, Amgen, AstraZeneca, Bayer, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardinal Health, CardioValve, CorFlow Therapeutics, CSL Behring, Daiichi Sankyo, Edwards Lifesciences, Guerbet, InfraRedx, Janssen-Cilag, Johnson & Johnson, Medicure, Medtronic, Merck Sharp & Dohm, Miracor Medical, Novartis, Novo Nordisk, Organon, OrPha Suisse, Pfizer, Polares, Regeneron, Sanofi-Aventis, Servier, Sinomed, Terumo, Vifor, and V-Wave; and serves as advisory board member and/or member of the steering/ Publisher Copyright: {\textcopyright} Europa Digital & Publishing 2023. All rights reserved.",
year = "2023",
doi = "10.4244/EIJ-D-23-00086",
language = "English",
volume = "19",
pages = "493--501",
journal = "EuroIntervention",
issn = "1774-024X",
publisher = "Europa Digital & Publishing",
number = "6",
}